The sixteen chapters of Advances in Ovarian Cancer Management present a concise, timely and comprehensive overview on the current status of the etiology, diagnosis and treatment of women
with epithelial ovarian cancer.
Therefore, new treatment modalities and paradigms are needed in order to significantly improve the prognosis of women diagnosed
with epithelial ovarian cancer.
Not exact matches
They also found differences in the types of bacteria in the upper reproductive tracts of women
with and without
epithelial ovarian cancer.
In the Oncogene study, DrugPredict produced a prioritized list of 6,996 chemicals
with potential to treat
epithelial ovarian cancer.
In that randomized, double - blind, placebo - controlled, phase III trial, 561 patients
with recurrent
epithelial ovarian, fallopian tube, or primary peritoneal
cancer who were in complete or partial response to platinum - based chemotherapy were treated
with either rucaparib 600 mg orally twice daily (372 patients) or to placebo (189 patients).
The LION trial randomized 650 patients
with advanced
epithelial ovarian cancer and macroscopic complete resection to either systematic pelvic and para-aortic LNE (323 patients in intention - to - treat cohort), or no LNE (324 patients in intention - to - treat cohort).
ZEJULA is the first and only once - daily PARP inhibitor for the maintenance treatment of adult patients
with recurrent
epithelial ovarian, fallopian tube, or primary peritoneal
cancer who are in a complete or partial response to platinum - based chemotherapy.1 - 3
ZEJULA is indicated for the maintenance treatment of adult patients
with recurrent
epithelial ovarian, fallopian tube, or primary peritoneal
cancer who are in a complete or partial response to platinum - based chemotherapy.
In collaboration
with the Institut Curie hospital, we are currently investigating origin and consequences of centrosome abnormalities in
epithelial ovarian cancers (EOC).
c. Epigenetic approaches to primer for and / or synergize
with immunological therapy in
epithelial ovarian cancer.
FORWARD1: A Randomized, Open Label Phase 3 Study to Evaluate the Safety and Efficacy of Mirvetuximab Soravtansine (IMGN853) Versus Investigator's Choice of Chemotherapy in Women
with Folate Receptor Alpha - Positive Advanced
Epithelial Ovarian Cancer, Primary Peritoneal
Cancer or Fallopian Tube
Cancer
The FDA has granted approval of rucaparib for maintenance therapy in patients
with recurrent
epithelial ovarian, fallopian tube, or primary peritoneal
cancer.